|
EQS-News: Redcare Pharmacy N.V.
/ Key word(s): Regulatory Approval
Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.
Sevenum, the Netherlands, 23 April 2024. Today, Redcare Pharmacy has successfully obtained the provider approval by the gematik for its eHealth-CardLink solution, while its development partner eHealth Experts simultaneously received the product approval. This innovative redemption method ensures that patients in Germany have access to a low-threshold, fully digital channel to obtain prescription drugs from their pharmacy of choice. Redcare’s eHealth-CardLink solution will be launched in its mobile app for customers in Germany by early May, following the implementation of all necessary technical and process steps. Redcare Pharmacy’s CEO, Olaf Heinrich comments: “This is a significant milestone for Redcare Pharmacy as well as for the broader digital transformation of the healthcare landscape in Germany. The complete benefits of a digitised prescription can now be fully realised by patients. By simply using the eGK health card, a smartphone and our app patients can redeem their prescription from anywhere and at any time.” The eHealth-CardLink solution is an additional redemption method for e-prescriptions to the existing eGK plug-in solution available in brick-and-mortar pharmacies, the gematik app and the printed version of the e-prescription with QR code. Customers of online pharmacies will still be able to use the gematik app or scan the QR code on the printed prescription. However, use of the eHealth-CardLink option does not require an eGK PIN – needed to use the gematik app – and provides a paperless, fully digital redemption journey. The e-prescription has been mandatory since January 2024, significantly accelerating the adoption rate by healthcare professionals. It is estimated that more than 70% of prescriptions issued to patients with statutory health insurance are now electronic. The German pharmaceutical market for prescription drugs is one of the largest in Europe, with an estimated volume of around EUR 50 billion. "Our solution meets the growing demand for digital, convenient and secure healthcare solutions and promises significant growth opportunities for us over the coming years", Olaf Heinrich added.
Investor Relations Contact: Monica Ambrosi (Associate Director, Investor Relations) investors@redcare-pharmacy.com
Press Contact: Sven Schirmer (Director, Corporate Communications)
About Redcare Pharmacy Originally founded in 2001, Redcare Pharmacy N.V. (formerly known as Shop Apotheke Europe N.V.) today is the leading e-pharmacy in Europe, currently active in seven countries: Germany, Austria, France, Belgium, Italy, the Netherlands and Switzerland. Headquartered in Sevenum, close to the Dutch city of Venlo and in the heart of Europe, the company has locations in Cologne, Berlin, Munich, Tongeren, Warsaw, Milan, Lille and Eindhoven. As the one-stop pharmacy of the future, Redcare Pharmacy offers over 11 million active customers a wide range of more than 150,000 products at attractive and fair prices. Besides OTC, nutritional supplements, beauty and personal care products as well as an extensive assortment of health-related products in all markets, the company also provides prescription drugs for customers in Germany, Switzerland and the Netherlands. Pharmaceutical safety is of top priority. Being a pharmacy at its core, Redcare stands for comprehensive pharmaceutical consultation service. Since care is at the heart of everything Redcare does, the company provides services for all stages of life and health. This ranges from its marketplaces to unique delivery options and medication management. Redcare Pharmacy N.V. has been listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard) since 2016. As of 19 June 2023, the company is a member of the MDAX selection index.
23.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Redcare Pharmacy N.V. |
| Erik de Rodeweg 11-13 | |
| 5975 WD Sevenum | |
| Netherlands | |
| Phone: | 0800 - 200 800 300 |
| Fax: | 0800 - 90 70 90 20 |
| E-mail: | investors@redcare-pharmacy.com |
| Internet: | www.redcare-pharmacy.com |
| ISIN: | NL0012044747, DE000A19Y072 |
| WKN: | A2AR94, A19Y072 |
| Indices: | MDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1887367 |
| End of News | EQS News Service |
|
|
1887367 23.04.2024 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
